Sponsored Content for Nathan Smith

Early-stage biotech NeuroScientific Biopharmaceuticals has delivered real-world promise for those living with chronic Crohn's disease following recent findings from its StemSmart cell therapy. Prescribed under Australia's Special Access Scheme, the results showed a strong clinical response in some of Crohn's disease's toughest patients, giving the company valuable validation, sharper trial design and a clearer pathway into a multi-billion-dollar global market.

NeuroScientific Biopharmaceuticals has reached another clinical milestone, with a fourth Crohn's disease patient now receiving its patented StemSmart stem cell therapy for the chronic bowel disease under Australia's Special Access Scheme. The company says data from the real-world program will directly inform the design of its upcoming phase two trial, slated to begin in the second half of 2026.

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals is transferring its patented StemSmart technology to one of Australia's biggest and most experienced manufacturers to scale up clinical-grade production, ahead of the commercialisation of its infusion therapy for hard-to-treat conditions, starting with Crohn's disease. Queensland-based Q-Gen Cell Therapeutics specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control.